ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Merck KGaA has synthesized transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer.

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

On Monday, plaintiffs’ lawyers filed their opening brief asking the U.S. Court of Appeals for the Fourth Circuit to reinstate ...

German pharmaceutical giant Merck has completed a €3 billion ($3.5 billion) takeover of US biopharmaceutical company ...

Uterine cancer incidence and mortality rates are projected to increase significantly over the next three decades in the ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Anal cancer screening among men who have sex with men with HIV aged 35 years and older appeared cost-effective and could decrease anal cancer incidence and mortality, according to research published ...